Literature DB >> 8075195

Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening.

L G Arnesson1, S Smeds, G Fagerberg.   

Abstract

OBJECTIVE: To evaluate survival of women with small breast cancers (10 mm or less in diameter) in a series almost unaffected by adjuvant medical treatment.
DESIGN: Prospective study from a population who were randomly allocated to be screened by mammography.
SETTING: University Hospital.
SUBJECTS: 324 patients with breast cancers 10 mm or less in diameter who were operated on between 1978-85 (230 detected by screening, 21 interval cases and 73 from the control group). MAIN OUTCOME MEASURES: Recurrence free survival, recurrence rate, and breast cancer mortality alone and in relation to node involvement during a median follow up of 7 years (range 4 months-12.5 years).
RESULTS: Survival without distant metastases in life table analyses was 98.7% in 254 node negative cases and 79.3% in 30 node positive cases (p < 0.001). For the whole series survival without distant recurrence was 96.8%. There was no significant difference in recurrence free survival between cancers detected by screening and those detected clinically. Lymph nodes were involved in 9% of the 221 detected by screening compared with 20% of the 89 detected clinically (p < 0.03).
CONCLUSION: There was a very low risk of recurrence in small node negative breast cancers (irrespective of the method of detection) indicating that adjuvant treatment may not be necessary for patients with small node negative breast tumours. The good prognosis of these patients also implies that the need for follow up programmes must be discussed because they are probably unnecessary.

Entities:  

Mesh:

Year:  1994        PMID: 8075195

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  8 in total

1.  Do all patients with breast cancer require systemic adjuvant therapy?

Authors:  Jennifer J Griggs; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-08-31       Impact factor: 13.506

2.  Can we select which patients with small breast cancers should receive adjuvant chemotherapy?

Authors:  William C Wood; Marge Anderson; Robert H Lyles; Toncred M Styblo; Douglas Murray; Charles Staley; Lily Yang; Grant Carlson
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

Review 3.  Adjuvant chemotherapy for tumors of one centimeter or less: the law of diminishing returns.

Authors:  S E Soule; K D Miller
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

4.  Near-diploid hyperploidy in early breast cancer (T1a,b) is associated with higher risk of lymph node involvement.

Authors:  Joško Bezić; Ivana Samija-Projić; Petar Projić; Jelena Ljubković; Sandra Tomaš-Zekić; Maja Marinović-Guić; Snježana Tomić
Journal:  Pathol Oncol Res       Date:  2012-08-28       Impact factor: 3.201

5.  Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.

Authors:  Mary C Schroeder; Charles F Lynch; Taher Abu-Hejleh; Elizabeth A Chrischilles; Alexandra Thomas
Journal:  Clin Breast Cancer       Date:  2014-08-18       Impact factor: 3.225

6.  Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.

Authors:  Stefania Gori; Matteo Clavarezza; Salvatore Siena; Jennifer Foglietta; Emiliana Tarenzi; Monica Giordano; Annamaria Molino; Claudio Graiff; Vittorio Fusco; Oscar Alabiso; Editta Baldini; Teresa Gamucci; Giuseppe Altavilla; Davide Dondi; Marco Venturini
Journal:  BMC Cancer       Date:  2012-04-30       Impact factor: 4.430

7.  Minimal breast cancer: evaluation of histology and biological marker expression.

Authors:  E A Dublin; R R Millis; P Smith; L G Bobrow
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

Review 8.  Screening for breast cancer with mammography.

Authors:  Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.